Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)
ID: 357017Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357017

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-198.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) aimed at advancing research in the development of next-generation human cell-derived microphysiological systems (MPS) that accurately replicate complex nervous system physiology. This funding opportunity, under the R01 Research Project Grant mechanism, encourages innovative applications that focus on enhancing existing technologies and creating sophisticated models for studying the nervous system's development, function, and aging, while explicitly excluding clinical trial projects. Eligible applicants include a diverse range of organizations, such as educational institutions and community-based organizations, with no specific budget limits as long as costs align with the proposed research. Interested parties should note that the application submission period opens on January 3, 2025, with a closing date of January 7, 2026, and are encouraged to contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-198-Full-Announcement.html
    PAR-25-198.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a Notice of Funding Opportunity (NOFO) designed to stimulate research in developing next-generation human cell-derived microphysiological systems (MPS) that accurately replicate complex nervous system physiology. The funding, under the R01 Research Project Grant mechanism, aims to improve existing technologies and create sophisticated models for studying the nervous system's development, functioning, and aging. Applications are encouraged from a diverse array of eligible organizations, including educational institutions and for-profit entities. The project period can extend up to five years, with no specific budget limits, as long as costs align with the proposed research. Review criteria emphasize innovation, scientific rigor, and the potential impact of the proposed technologies. The NOFO specifically targets projects not focused on clinical trials and excludes applications centered around scalable assays or regenerative medicine strategies. Key dates for submission include an earliest opening date of January 3, 2025, and subsequent application deadlines. Interested applicants are urged to engage with NIH contact personnel to align their proposals with specific institute interests, such as mental health, aging, and alcohol abuse research.
    Similar Opportunities
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)," aimed at advancing research in human cell-derived microphysiological systems (MPS) that replicate complex nervous system architectures and functions. This initiative seeks innovative applications that address technological barriers in studying nervous system development and diseases, with a focus on improving physiological relevance and circuit-level activity in existing assays. The funding is open to a wide range of eligible applicants, including higher education institutions and non-profits, with a project period of up to five years and no cost-sharing requirement. Interested parties should note that the application deadline is January 7, 2026, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the announcement page at https://grants.nih.gov/grants/guide/pa-files/PAR-23-046.html.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 grant mechanism to support the development of next-generation human cell-derived microphysiological systems (MPS) that accurately replicate the architectures and functions of the human nervous system. This initiative aims to encourage high-risk, high-reward exploratory research, particularly relevant for addressing complex nervous system disorders, and is open to a diverse range of eligible applicants, including educational institutions, non-profits, and governmental entities. The funding, capped at $275,000 over a two-year period, emphasizes collaboration among experts in neurobiology, engineering, and ethics, and applications must adhere to NIH data management and sharing policies. Interested parties can find more information and submit inquiries via grantsinfo@nih.gov, with the application deadline set for January 7, 2026.
    Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)" aimed at supporting innovative research in the identification and development of novel compounds for the prevention and treatment of nervous system disorders. This initiative encourages applications focused on early-stage research, particularly in the areas of small molecules, biotechnology products, and biologics, with an emphasis on projects that utilize machine learning and propose preclinical evaluations of candidate drugs. The funding amount available is up to $275,000, with a submission deadline of January 7, 2025. Interested applicants can find more information and submission guidelines at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)," aimed at advancing research on high-confidence risk factors associated with complex brain disorders. This grant encourages studies that focus on the intracellular, transcellular, and circuit substrates of neural function, allowing for both hypothesis-generating and hypothesis-testing research designs, while discouraging attempts to model the disorders themselves. The initiative is crucial for enhancing understanding of the biological processes impacted by these disorders, ultimately facilitating therapeutic target identification and enriching data resources. Applications are due by September 7, 2026, with no budget cap, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the R21 Clinical Trial Not Allowed grant, aimed at advancing research into the cellular and molecular biology of complex brain disorders. This funding opportunity encourages innovative research focused on high-confidence risk factors associated with conditions such as schizophrenia, major depression, and anxiety, emphasizing hypothesis-generating studies rather than disorder modeling. The grant supports projects with budgets up to $275,000 over a two-year period, with applications due starting January 16, 2025, and a closing date of September 7, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-037.html.
    BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System," aimed at advancing neuroscience research through innovative technology development. This initiative seeks applications for the creation of new hardware, software, or molecular constructs that address challenges in recording and modulating neural cells and circuits, with a focus on high-risk projects that could lead to transformative outcomes in understanding dynamic signaling within the central nervous system. The program allocates an estimated $10 million annually for 15-20 awards, emphasizing collaboration across scientific domains and encouraging participation from diverse institutions, particularly those supporting early-career researchers and underserved populations. Interested applicants should note that the application submission deadlines begin on May 2, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R01 Research Project Grant aimed at advancing drug discovery for nervous system disorders. This initiative focuses on the identification, design, synthesis, and preclinical testing of novel therapeutic compounds, particularly emphasizing innovative approaches to drug metabolism and pharmacokinetics, while excluding clinical trial applications. The program encourages high-risk, novel projects that aim to translate scientific research into effective treatments for conditions such as mental illness and substance use disorders. Interested applicants can find more information and guidelines in the NIH Grant Application Guide, with applications due by January 7, 2025. For inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovation Grants to Nurture Initial Translational Efforts (IGNITE)" aimed at developing and validating model systems for neurotherapeutic discovery. This initiative encourages proposals for animal models or ex vivo systems that accurately replicate the characteristics of specific neurological or neuromuscular disorders, with the goal of enhancing the translational relevance of these models to improve drug development processes. The program utilizes a phased award mechanism (R61/R33) and requires collaboration with clinical experts, along with a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research. The total funding available is $750,000 over three years, with a maximum of $499,000 in direct costs per year. Key submission dates begin with the earliest application due date of January 18, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the BRAIN Initiative, titled "New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed)." This initiative aims to support proof-of-concept testing and the development of innovative neurotechnologies that can enhance the understanding of brain circuit dynamics and facilitate transformative neuroscience research. The program encourages high-risk, high-impact projects that integrate diverse scientific domains and require applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of their proposals. The total estimated funding available is $10 million annually, with plans to support 15-20 awards over a maximum project period of three years. Interested applicants must adhere to strict submission guidelines, and the application deadline is January 20, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.